GCP
STLN

GSA Capital Partners’s Starling Oncology STLN Stock Holding History

GSA Capital Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536K Buy
+98,727
New +$415K 0.03% 957
2026
Q1 		– Sell
-70,654
Closed -$252K – 2157
2025
Q4 		$252K Buy
+70,654
New +$262K 0.02% 1270
2025
Q2 		– Sell
-28,529
Closed -$33K – 2152
2025
Q1 		$33K Buy
+28,529
New +$22.1K ﹤0.01% 1567

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSA Capital Partners's STLN Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Starling Oncology (STLN) in Q2 2026: 98,727 shares worth $536K. The stake represents 0.03% of the portfolio and ranks #957 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in STLN as recently as Q4 2025.

GSA Capital Partners first reported a position in STLN in Q1 2025 and has held it in 3 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • GSA Capital Partners held 98,727 shares of Starling Oncology worth $536K as of Q2 2026.
  • Starling Oncology was a new GSA Capital Partners position in Q2 2026.
  • Starling Oncology made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #957 holding.
  • GSA Capital Partners first reported a position in Starling Oncology in Q1 2025 and has held it in 3 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.